On the stock market since 2007, it operates in the world of health and science. Now — the numbers.
The stock trades 50% below its peak. The market has trimmed its expectations for the company.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
The stock sits at $0.0002. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, AGGX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: AGGX is a high-risk stock — not yet profitable, and its future rides on its product catching on.